Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 vs Durvalumab After cCRT in Unresectable Stage III NSCLC
CTR20200028Phase 3Terminated
- Sponsor
- Merck Serono
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bintrafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Merck Serono. Started Jul 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200028.